Tesamorelin
Overview
Tesamorelin (trade name Egrifta) is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that regulates pituitary GH secretion. Structurally, it consists of the full 44 amino acid sequence of human GHRH(1-44) with the addition of a trans-3-hexenoic acid moiety at the N-terminus, a modification that confers enhanced stability against degradation by dipeptidyl peptidase IV (DPP-IV) — the primary enzyme responsible for inactivating endogenous GHRH in circulation.
Tesamorelin is the only GHRH analog to receive FDA approval, which it obtained in 2010 under the indication of reducing excess abdominal fat (lipodystrophy) in HIV-positive patients receiving antiretroviral therapy. This clinical pedigree distinguishes it sharply from most research peptides: the compound has been evaluated in randomized, double-blind, placebo-controlled Phase III human trials with well-characterized primary endpoints, robust safety monitoring, and published results in high-impact peer-reviewed journals including the New England Journal of Medicine.
The compound's mechanism — stimulating endogenous pituitary GH release rather than supplying exogenous GH directly — results in a pulsatile pattern of GH secretion that more closely mimics physiological rhythms than exogenous growth hormone administration. This property has made tesamorelin of considerable research interest beyond its approved indication, particularly in metabolic research, age-related GH decline, and cognitive function studies in older adults.
Tesamorelin also elevates insulin-like growth factor 1 (IGF-1 LR3) levels via the downstream GH-IGF-1 axis, providing a secondary research endpoint of interest in longevity and metabolic research contexts. Its well-characterized pharmacokinetic profile, established safety record, and available Phase III data make it one of the most rigorously studied GHRH analogs in existence.
Regulatory status: Tesamorelin is FDA-approved (Egrifta) for HIV-associated lipodystrophy. All research applications beyond this approved indication are investigational. For research use only.
Mechanism of Action
Tesamorelin acts as a full agonist at the GHRH receptor (GHRHR), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary gland. Binding of tesamorelin to GHRHR activates adenylyl cyclase via Gs protein coupling, increasing intracellular cyclic AMP (cAMP) concentrations. This cAMP signal cascade ultimately stimulates synthesis and pulsatile secretion of growth hormone from pituitary somatotrophs into systemic circulation.
DPP-IV Resistance and Enhanced Stability
Native GHRH(1-44) has an extremely short plasma half-life — on the order of 6–7 minutes — due to rapid N-terminal cleavage by DPP-IV. Tesamorelin's N-terminal trans-3-hexenoic acid modification sterically blocks this enzymatic cleavage site, extending the compound's functional half-life to approximately 26 minutes (IV) and 38 minutes (SC). This represents a roughly four- to five-fold improvement over native GHRH, making tesamorelin substantially more practical for research and clinical applications requiring sustained GHRH receptor stimulation.
GH Pulsatility and IGF-1 Upregulation
Unlike exogenous recombinant human GH, which delivers a constant pharmacological dose, tesamorelin works by amplifying the pituitary's own GH secretory capacity. The result is pulsatile GH release that preserves the natural feedback loops governing the GH-IGF-1 axis. Circulating GH then stimulates hepatic production of IGF-1, which mediates many of GH's downstream anabolic and metabolic effects. In Phase III clinical trials, tesamorelin 2 mg SC daily produced consistent, statistically significant increases in IGF-1 levels compared to placebo — an effect that was reversible upon discontinuation, confirming the compound's mechanism is dependent on ongoing receptor stimulation rather than permanent axis alteration.
Visceral Fat Reduction
The downstream metabolic consequence most relevant to tesamorelin's approved indication is its documented ability to reduce visceral adipose tissue (VAT). Growth hormone stimulates lipolysis — the mobilization and oxidation of fatty acids from adipocytes — through activation of hormone-sensitive lipase and suppression of lipoprotein lipase activity in fat tissue. In HIV-associated lipodystrophy, where antiretroviral therapy suppresses endogenous GH pulsatility and promotes visceral fat accumulation, tesamorelin restores GH signaling and produces measurable reductions in trunk fat as measured by DEXA and CT imaging.
Somatostatin Feedback Preservation
Because tesamorelin stimulates rather than replaces endogenous GH secretion, the normal somatostatin-mediated negative feedback mechanism remains intact. Somatostatin, released from the hypothalamus, provides physiological braking on GH release — a regulatory loop that is bypassed entirely when exogenous GH is administered. The preservation of this feedback is thought to contribute to tesamorelin's favorable safety profile relative to exogenous GH, including lower incidence of supraphysiological GH excursions.
Research Studies
Tesamorelin's clinical data package is unusually robust for a research peptide. The following summaries cover the pivotal Phase III trials and key secondary studies that define the compound's documented pharmacological profile.
This was the pivotal Phase III randomized, double-blind, placebo-controlled trial that formed the basis of tesamorelin's FDA approval. 816 HIV-positive adults with lipodystrophy were randomized to tesamorelin 2 mg SC daily or placebo for 26 weeks. The primary endpoint was change in visceral adipose tissue volume as measured by CT scan. Tesamorelin produced a statistically significant 15.2% reduction in VAT compared to a 5.0% increase in the placebo group (p<0.001). Secondary endpoints including IGF-1 levels, trunk-to-limb fat ratio, and patient-reported satisfaction also showed significant improvement. The safety profile was characterized primarily by injection site reactions and fluid retention consistent with GH-related effects.
↓ 15.2% VAT reduction · ↑ IGF-1 · Significant vs. placebo (p<0.001)This 52-week extension study followed participants who completed the initial Phase III trial, examining whether tesamorelin's metabolic effects were sustained with continued treatment. Patients who remained on tesamorelin maintained their VAT reductions at 52 weeks, while those who switched from tesamorelin to placebo experienced significant VAT rebound, demonstrating that ongoing treatment is required to sustain the compound's effects. IGF-1 levels similarly returned toward baseline upon discontinuation. This study confirmed tesamorelin's effects are treatment-dependent and fully reversible, with no evidence of pituitary desensitization over the 52-week observation window.
Sustained VAT reduction at 52 weeks · Reversible upon discontinuation · No pituitary desensitizationThis randomized placebo-controlled trial evaluated whether tesamorelin could attenuate cognitive decline in older adults with mild cognitive impairment, based on the established link between GH/IGF-1 signaling and hippocampal neuroplasticity. Over 20 weeks, tesamorelin-treated subjects demonstrated improved performance on verbal memory tasks compared to placebo, with the effect correlating with IGF-1 elevation. While the sample size was modest and the findings require replication in larger cohorts, this study opened a significant new research direction for GHRH analogs beyond their metabolic applications.
↑ Verbal memory performance · ↑ IGF-1 · Correlation between IGF-1 and cognitionAn earlier Phase II study examining tesamorelin's effects on the lipid panel in HIV-infected patients with lipodystrophy. Treatment with 2 mg SC daily produced significant reductions in triglyceride levels and improvements in the triglyceride-to-HDL ratio — cardiovascular risk markers that are frequently elevated in this patient population. These findings suggested tesamorelin's metabolic benefits extend beyond VAT reduction to include favorable effects on circulating lipid fractions, likely mediated through GH's role in hepatic lipid metabolism.
↓ Triglycerides · ↑ HDL ratio · Improved cardiovascular risk markersDosage Research
Important: The following dosage data is sourced from published clinical trial literature and is provided for research reference only. Tesamorelin is FDA-approved at 2 mg SC daily for its labeled indication. All other research applications are investigational.
Unlike most research peptides for which dosage data derives exclusively from animal studies, tesamorelin's dosage parameters are well-established in human clinical trial literature. The uniformity of dosing across major trials reflects a clearly characterized dose-response relationship established during Phase II development.
| Study Context | Population | Route | Dosage | Duration |
|---|---|---|---|---|
| HIV lipodystrophy — Phase III (Falutz 2010) | Human (HIV+) | Subcutaneous | 2 mg once daily | 26 weeks |
| Long-term extension (Stanley 2012) | Human (HIV+) | Subcutaneous | 2 mg once daily | 52 weeks |
| Cognitive function (Baker 2021) | Human (older adults) | Subcutaneous | 1 mg once daily | 20 weeks |
| Phase II lipid/metabolic study (Falutz 2008) | Human (HIV+) | Subcutaneous | 1–2 mg once daily | 12 weeks |
| Rodent metabolic models | Rat | Subcutaneous | 100–300 µg/kg | Variable |
The consistent 2 mg SC once-daily dose used across the pivotal clinical trials reflects the compound's pharmacokinetic profile — its half-life of approximately 38 minutes subcutaneously necessitates daily administration to maintain cumulative pituitary GH stimulation. Morning administration is conventionally used in clinical studies to align with the physiological diurnal GH peak.
Use the Alpha Tides Peptide Calculator to perform reconstitution math for research applications.
Half-Life
Tesamorelin's pharmacokinetic profile is among the best characterized of any research GHRH analog, owing to its clinical trial data package. Formal PK studies with multiple sampling timepoints have been published, providing direct measurement of plasma half-life rather than estimation from dosing interval inference.
| Parameter | Value | Notes |
|---|---|---|
| Half-life (IV) | ~26 minutes | Direct PK measurement in clinical studies |
| Half-life (SC) | ~38 minutes | Accounts for absorption lag; terminal elimination phase |
| Time to peak (SC) | ~15 minutes | Tmax for plasma concentration after SC injection |
| GH peak (post-dose) | 15–45 minutes | GH pulsatile release follows tesamorelin Tmax |
| IGF-1 elevation | Sustained (days) | IGF-1 has its own, much longer half-life (~15 hours) |
| Mechanism of clearance | Proteolytic degradation | Primarily peptidase-mediated; renal excretion minor |
The relatively short plasma half-life of tesamorelin — even with its DPP-IV resistance modification — means the compound is rapidly cleared from systemic circulation after each dose. The biological signal, however, persists considerably longer because downstream effects (pituitary GH release, hepatic IGF-1 production) outlast the peptide's plasma presence. This pharmacokinetic-pharmacodynamic disconnect is a common and important feature of GHRH analogs and growth hormone secretagogues.
For half-life data on additional compounds including Ipamorelin and CJC-1295, see the Peptide Half-Life Reference Chart.
Storage & Stability
Tesamorelin is supplied as a lyophilized (freeze-dried) powder, consistent with standard research peptide presentation. The compound's stability characteristics are well-documented from clinical manufacturing standards established during its FDA approval process.
| State | Storage Condition | Estimated Stability |
|---|---|---|
| Lyophilized (unreconstituted) | −20°C, protected from light | 24+ months |
| Lyophilized (unreconstituted) | 2–8°C, protected from light | 3–6 months |
| Reconstituted in BAC water | 2–8°C, protected from light | 4–6 weeks |
| Reconstituted — avoid | Room temperature or above | Rapid degradation |
Key Handling Notes
- Store lyophilized tesamorelin at −20°C in a sealed vial. Protect from humidity and light exposure.
- Once reconstituted, refrigerate at 2–8°C and use within 4–6 weeks. Do not freeze reconstituted solution.
- Bacteriostatic water (BAC water) is the recommended reconstitution solvent for extended stability of reconstituted solution.
- The N-terminal trans-3-hexenoic acid modification does not materially affect standard storage requirements relative to other peptides.
- Swirl gently during reconstitution — avoid vigorous shaking which can cause aggregation.
- Use aseptic technique at all times when handling reconstituted peptides.
See the full Peptide Reconstitution Protocol for complete laboratory procedures.
Summary
Tesamorelin occupies a unique position in the GHRH analog research space: it is the only compound of its class to have completed Phase III human clinical trials and received FDA approval, providing a level of evidence that is simply not available for most research peptides. Its documented efficacy in reducing visceral adipose tissue in HIV-associated lipodystrophy — confirmed across multiple randomized controlled trials — establishes a solid pharmacodynamic foundation for understanding how GHRH receptor stimulation affects metabolic outcomes.
The compound's mechanism of action — preserving pulsatile GH secretion and the somatostatin feedback loop — distinguishes it from exogenous GH administration and makes it an important research comparator for understanding the physiological consequences of GH axis stimulation under more naturalistic conditions. Its downstream effects on IGF-1 provide a convenient secondary biomarker for research endpoints related to growth factor signaling.
Emerging research into tesamorelin's effects on cognitive function and neural health represents an important new frontier, supported by the mechanistic link between IGF-1 and hippocampal neuroplasticity. While larger trials are needed to confirm the cognitive findings, the existing signal is scientifically plausible and experimentally reproducible in the published literature.
For research applications involving GHRH axis stimulation, tesamorelin's characterized pharmacokinetics, established human dosing parameters, and robust safety data provide a strong reference framework. Compounds like Ipamorelin and CJC-1295 address related but mechanistically distinct aspects of GH secretagogue research.
References
- Falutz J, Mamputu JC, Potvin D, et al. "Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Abdominal Fat Accumulation." N Engl J Med. 2010;362(23):2109–2119. PMID: 20375405. PubMed →
- Stanley TL, Falutz J, Mamputu JC, et al. "Effects of Tesamorelin on Inflammatory Markers and Endothelial Function in HIV-Infected Patients with Abdominal Fat Accumulation." J Clin Endocrinol Metab. 2012;97(7):E1091–E1098. PMID: 22674664. PubMed →
- Baker LD, Barsness SM, Borson S, et al. "Effects of Growth Hormone-Releasing Hormone on Cognitive Function in Adults with Mild Cognitive Impairment and Healthy Older Adults." JAMA Neurol. 2021;78(7):776–785. PMID: 33165506. PubMed →
- Falutz J, Allas S, Blot K, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." J Clin Endocrinol Metab. 2008;93(6):2244–2250. PMID: 18460559. PubMed →
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683. PubMed →
- Popovic V, Damjanovic S, Micic D, et al. "Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level." J Clin Endocrinol Metab. 1995;80(3):942–947. PMID: 7883856. PubMed →
- Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. "Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy." Am J Physiol Endocrinol Metab. 2004;286(3):E476–E483. PMID: 14600069. PubMed →
- Laferrère B, Hart AB, Bowers CY. "Obese subjects respond to the stimulatory effect of the ghrelin agonist GHRP-2 on 24-h growth hormone profiles." Obes Res. 2006;14(6):1009–1016. PMID: 16861613. PubMed →